CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma-Reference-Cited by-同舟云学术

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma

Published:2003-08-01 Issue:3 Volume:102 Page:1070-1071
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Robillard Nelly¹,Avet-Loiseau Hervé¹,Garand Richard¹,Moreau Philippe¹,Pineau Danielle¹,Rapp Marie-Josée¹,Harousseau Jean-Luc¹,Bataille Régis¹

Affiliation:

1. From the Laboratory of Hematology and Institut National de la Santé et de la Recherche Médicale (INSERM) U463, Institute of Biology, Nantes, France; and Department of Clinical Hematology, Nantes, Cedex 01, France

Abstract

Abstract CD20 has been reinvestigated in 66 patients with multiple myeloma (MM). Twelve of the patients (18%) expressed CD20, including 5 of 50 patients at diagnosis presenting 100% CD20+ cells. Seven (58%) of 12 CD20+ patients with MM had a small mature plasma cell morphology as opposed to 4 (7%) of 54 with CD20- MM (P = .0001). Of note, 10 (83%) of 12 patients with CD20+ MM had t(11;14) as opposed to 5 of 54 (9%) CD20- patients (P < .001). All the patients with 100% CD20+ cells presented with t(11;14) and 4 of 5 with a small mature plasma cell morphology. Thus, 66% of the patients with t(11;14) expressed CD20, whereas only 4% of the 51 patients lacking such translocation expressed CD20 (P < .0001). In conclusion, CD20 expression is associated with small mature plasma cell morphology and with t(11;14) in patients with MM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/102/3/1070/1688950/h81503001070.pdf

Reference17 articles.

1. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features and clinical presentation. Blood. 2002;99: 2185-2191.

2. Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100: 1579-1583.

3. Jackson N, Ling NR, Ball J, Bromidge E, Nathan PD, Franklin IM. An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd international workshop on human leucocyte differentiation antigens. Clin Exp Immunol.1988;72: 351-356.

4. San Miguel F, Gonzalez M, Gascon A, et al. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of disease. Br J Haematol.1991;77: 185-190.

5. Leo R, Boeker M, Peest D, et al. Multiparameter analyses of normal and malignant human plasma cells: CD 38++, CD56+, cIg+ is the common phenotype of myeloma cells. Ann Hematol.1992;64: 132-139.

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for multiple myeloma: The case for translocation (11;14);Cancer Treatment Reviews;2024-11

2. Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia;Cancer Medicine;2024-09

3. Biomarker-directed therapy in multiple myeloma;Current Opinion in Oncology;2024-08-23

4. Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency;Blood;2024-01-04

5. Anti-CD20 antibody treatment for B-cell malignancies;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024